US FDA Approves SKYRIZI^® for Ulcerative Colitis, Expanding AbbVie’s Portfolio across Inflammatory Bowel Disease

AbbVie announced the US FDA has approved SKYRIZI®(risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn’s disease.3